CorMedix Set for Breakout with DefenCath's Outpatient Launch
AI Prediction of CorMedix Inc. (CRMD)
CorMedix, a biopharmaceutical company focused on developing and commercializing therapeutic products, shows promise with its lead product, DefenCath. Recent FDA approval and subsequent commercial launch plans indicate potential growth. The upcoming PDUFA date and commercial roll-out in outpatient settings could serve as significant catalysts, impacting the stock positively.
CRMD Report Information
Prediction Date2025-07-03
Close @ Prediction$11.62
Mkt Cap494m
IPO Date2010-05-13
AI-derived Information
Recent News for CRMD
- Mar 6, 8:30 am — CorMedix Inc. Q4 2025 Earnings Call Summary (Moby)
- Mar 5, 8:18 pm — CorMedix Q4 Earnings Call Highlights (MarketBeat)
- Mar 5, 4:04 pm — Cormedix Inc (CRMD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
- Mar 5, 8:50 am — CorMedix (CRMD) Lags Q4 Earnings Estimates (Zacks)
- Mar 5, 7:56 am — CorMedix: Q4 Earnings Snapshot (Associated Press Finance)
- Mar 5, 7:30 am — CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
- Mar 2, 8:30 am — CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 (GlobeNewswire)
- Feb 27, 8:05 am — ANI Pharmaceuticals (ANIP) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
- Feb 26, 8:05 pm — Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
- Feb 24, 8:02 am — CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet? (Zacks)
- Feb 23, 10:45 am — Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings? (Zacks)
- Feb 17, 10:30 am — CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock? (Zacks)
NDAPR (News-Driven AI Prediction Revision) events for CRMD
-
Jan 23, 12:08 pmRevision: NO_CHANGE | Price Pressure Direction: YES_DOWN | Thesis Unchanged?: NORationale: Revised revenue forecasts and increased competition undermine growth expectations.
-
Jan 20, 10:42 amRevision: NO_CHANGE | Price Pressure Direction: NONE | Thesis Unchanged?: YES_UNCHANGEDRationale: The news does not materially impact CorMedix's financial outlook or market position.
-
Jan 19, 11:31 amRevision: NO_CHANGE | Price Pressure Direction: NONE | Thesis Unchanged?: YES_UNCHANGEDRationale: Recent news does not materially impact CorMedix's core business or financial outlook.
-
Jan 15, 9:44 amRevision: NO_CHANGE | Price Pressure Direction: NONE | Thesis Unchanged?: YES_UNCHANGEDRationale: DefenCath's continued market exclusivity and revenue growth support the original bullish thesis.
-
Jan 12, 10:40 amRevision: NO_CHANGE | Price Pressure Direction: NONE | Thesis Unchanged?: YES_UNCHANGEDRationale: The breaking news does not directly impact CorMedix's operations or financials.
-
Jan 9, 8:32 amRevision: NO_CHANGE | Price Pressure Direction: NONE | Thesis Unchanged?: YES_UNCHANGEDRationale: Presentation at J.P. Morgan Healthcare Conference is routine, not materially impacting the stock's fundamentals.
-
Jan 8, 8:07 amRevision: NO_CHANGE | Price Pressure Direction: YES_UP | Thesis Unchanged?: YES_UNCHANGEDRationale: Strong financial results and positive business updates support continued bullish sentiment.
-
Jan 7, 10:59 amRevision: NO_CHANGE | Price Pressure Direction: NONE | Thesis Unchanged?: YES_UNCHANGEDRationale: The breaking news does not relate to CorMedix and does not impact the original investment thesis.
-
Jan 6, 6:32 pmRevision: NO_CHANGE | Price Pressure Direction: NONE | Thesis Unchanged?: YES_UNCHANGEDRationale: The breaking news does not directly impact CorMedix's operations or market position.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.